| 3.27 -0.32 (-8.91%) | 10-03 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 7.17 | 1-year : | 10 |
| Resists | First : | 6.14 | Second : | 8.56 |
| Pivot price | 2.95  |
|||
| Supports | First : | 2.22 | Second : | 1.84 |
| MAs | MA(5) : | 3.24 |
MA(20) : | 2.89 |
| MA(100) : | 8.14 |
MA(250) : | 18.04 |
|
| MACD | MACD : | -0.7 |
Signal : | -1 |
| %K %D | K(14,3) : | 19.4 |
D(3) : | 16.9 |
| RSI | RSI(14): 41.7 |
|||
| 52-week | High : | 58.24 | Low : | 2.22 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ INDP ] has closed below upper band by 30.7%. Bollinger Bands are 59.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 7 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 3.82 - 3.85 | 3.85 - 3.87 |
| Low: | 3.17 - 3.19 | 3.19 - 3.21 |
| Close: | 3.24 - 3.27 | 3.27 - 3.3 |
Indaptus Therapeutics, Inc., a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical oncology candidate is Decoy20 to single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as hepatitis B virus and human immunodeficiency virus infection, which is in Phase I clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. was incorporated in 2021 and is headquartered in New York, New York.
Fri, 05 Sep 2025
Indaptus Therapeutics stock falls after mixed clinical trial updates - Investing.com
Tue, 02 Sep 2025
Indaptus Therapeutics to Present at the H.C. Wainwright 27ᵗʰ Annual Global Investment Conference - GlobeNewswire
Tue, 02 Sep 2025
Biotech Indaptus Therapeutics Joins Major Healthcare Conference: CEO to Present Latest Developments - Stock Titan
Wed, 13 Aug 2025
Indaptus Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update - Yahoo Finance
Thu, 26 Jun 2025
Indaptus Therapeutics Announces Reverse Stock Split - TipRanks
Wed, 25 Jun 2025
Indaptus Therapeutics Sets 1-for-28 Reverse Stock Split - Nasdaq
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 1 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 19.6 (%) |
| Held by Institutions | 4.7 (%) |
| Shares Short | 547 (K) |
| Shares Short P.Month | 19 (K) |
| EPS | -37.39 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -2.77 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -136.6 % |
| Return on Equity (ttm) | -755.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -14.73 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -15 (M) |
| Levered Free Cash Flow | -9 (M) |
| PE Ratio | -0.09 |
| PEG Ratio | 0 |
| Price to Book value | -1.19 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.25 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|